shulz/E+ via Getty Images
Exicure (NASDAQ:XCUR) signed a MOU with GPCR Therapeutics aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines.
Through this acquisition, Exicure plans to secure
